Abstract:Abstract Cancer biomarkers have transformed current practices in the oncology clinic. Continued discovery and validation are crucial for improving early diagnosis, risk stratification, and monitoring patient response to treatment. Profiling of the tumour genome and transcriptome are now established tools for the discovery of novel biomarkers, but alterations in proteome expression are more likely to reflect changes in tumour pathophysiology. In the past, clinical diagnostics have strongly relied on antibody-based detection strategies, but these methods carry certain limitations. Mass spectrometry (MS) is a powerful method that enables increasingly comprehensive insights into changes of the proteome to advance personalized medicine. In this review, recent improvements in MS-based clinical proteomics are highlighted with a focus on oncology. We will provide a detailed overview of clinically relevant samples types, as well as, consideration for sample preparation methods, protein quantitation strategies, MS configurations, and data analysis pipelines currently available to researchers. Critical consideration of each step is necessary to address the pressing clinical questions that advance cancer patient diagnosis and prognosis. While the majority of studies focus on the discovery of clinically-relevant biomarkers, there is a growing demand for rigorous biomarker validation. These studies focus on high-throughput targeted MS assays and multi-centre studies with standardized protocols. Additionally, improvements in MS sensitivity are opening the door to new classes of tumour-specific proteoforms including post-translational modifications and variants originating from genomic aberrations. Overlaying proteomic data to complement genomic and transcriptomic datasets forges the growing field of proteogenomics, which shows great potential to improve our understanding of cancer biology. Overall, these advancements not only solidify MS-based clinical proteomics’ integral position in cancer research, but also accelerate the shift towards becoming a regular component of routine analysis and clinical practice.

Cancer proteogenomics: current impact and future prospects

Proteomics, Personalized Medicine and Cancer

A Review, Timeline, and Categorization of Learning Design Tools

Clinical potential of mass spectrometry-based proteogenomics

Proteogenomic characterization of human colon and rectal cancer

Oncoproteomics: current trends and future perspectives

Proteomics‐based interrogation of the kinome and its implications for precision oncology

Lung Cancer Proteogenomics: Shaping the Future of Clinical Investigation

Recent advances in mass spectrometry based clinical proteomics: applications to cancer research

The role of genomics in global cancer prevention

Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy

Proteomics to study cancer immunity and improve treatment

[Diffuse skin mastocytosis of nurslings. 3 clinical cases with bullous manifestations].

Proteomic and genomic profiling of pancreatic cancer

A Family with an atonic variant of paroxysmal kinesigenic choreoathetosis and hypercalcitoninemia

Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology

Mass Spectrometry–Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine

Proteomics in human cancer research

Is it 'oldtimer's disease' or just growing old?

Proteomics approaches to characterize the immune responses in cancer

Integrate and conquer: pan-cancer proteogenomics uncovers cancer vulnerabilities and therapeutic opportunities